• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
A Retrospective Study of the Use of Gonadotropin-Releasing Hormone Analogs and Testosterone in Transgender Boys: Who, What, When, and for How Long?一项关于变性男孩使用促性腺激素释放激素类似物和睾酮的回顾性研究：对象、药物、时间及使用时长？
Transgend Health. 2024 Aug 16;9(4):357-360. doi: 10.1089/trgh.2022.0156. eCollection 2024 Aug.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方：益处与风险
3
GnRH analogs as a monotherapy in transgender and gender-diverse adolescents: clinical insights from a single-center study.促性腺激素释放激素类似物作为跨性别和性别多样化青少年的单一疗法：一项单中心研究的临床见解
Endocr Connect. 2025 Aug 14;14(8). doi: 10.1530/EC-25-0292. Print 2025 Aug 1.
4
Pre-operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding.对于月经过多患者，在进行子宫内膜破坏术前使用的术前子宫内膜减薄剂。
Cochrane Database Syst Rev. 2013 Nov 15;2013(11):CD010241. doi: 10.1002/14651858.CD010241.pub2.
5
Prevalence of detransition in persons seeking gender-affirming hormonal treatments: a systematic review.寻求性别肯定激素治疗者中性别转变的发生率：一项系统综述。
J Sex Med. 2025 Jan 9;22(2):356-368. doi: 10.1093/jsxmed/qdae186.
6
Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density.用于子宫内膜异位症的促性腺激素释放激素类似物：骨矿物质密度
Cochrane Database Syst Rev. 2003;2003(4):CD001297. doi: 10.1002/14651858.CD001297.
7
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
8
Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.用于治疗月经过多的孕激素或释放孕激素的宫内节育系统。
Cochrane Database Syst Rev. 2015 Apr 30(4):CD002126. doi: 10.1002/14651858.CD002126.pub3.
9
Sexual Harassment and Prevention Training性骚扰与预防培训
10
Preoperative medical therapy before surgery for uterine fibroids.子宫肌瘤手术前的术前医学治疗。
Cochrane Database Syst Rev. 2017 Nov 15;11(11):CD000547. doi: 10.1002/14651858.CD000547.pub2.

本文引用的文献

1
Association of Gonadotropin-Releasing Hormone Analogue Use With Subsequent Use of Gender-Affirming Hormones Among Transgender Adolescents.促性腺激素释放激素类似物的使用与跨性别青少年后续使用性别肯定激素之间的关联。
JAMA Netw Open. 2022 Nov 1;5(11):e2239758. doi: 10.1001/jamanetworkopen.2022.39758.
2
Continuation of gender-affirming hormones in transgender people starting puberty suppression in adolescence: a cohort study in the Netherlands.青春期开始抑制性别认同激素的跨性别者继续使用：荷兰的一项队列研究。
Lancet Child Adolesc Health. 2022 Dec;6(12):869-875. doi: 10.1016/S2352-4642(22)00254-1. Epub 2022 Oct 21.
3
Approach to the Patient: Pharmacological Management of Trans and Gender-Diverse Adolescents.患者处理：跨性别和性别多样化青少年的药理学管理。
J Clin Endocrinol Metab. 2022 Jan 1;107(1):241-257. doi: 10.1210/clinem/dgab634.
4
Systematic Review: Puberty suppression with GnRH analogues in adolescents with gender incongruity.系统评价：促性腺激素释放激素类似物在性别不一致青少年中的青春期抑制作用。
J Endocrinol Invest. 2021 Jun;44(6):1151-1158. doi: 10.1007/s40618-020-01449-5. Epub 2020 Oct 28.
5
Timing of Puberty Suppression and Surgical Options for Transgender Youth.青春期抑制的时机和 transgender 青年的手术选择。
Pediatrics. 2020 Nov;146(5). doi: 10.1542/peds.2019-3653.
6
The experiences of gender diverse and trans children and youth considering and initiating medical interventions in Canadian gender-affirming speciality clinics.加拿大性别肯定专科诊所中性别多元及跨性别儿童和青少年考虑并开始接受医学干预的经历。
Int J Transgend. 2019 Aug 30;20(4):371-387. doi: 10.1080/15532739.2019.1652129. eCollection 2019.
7
Trends in Referrals to a Pediatric Transgender Clinic.儿科跨性别诊所转诊趋势。
Pediatrics. 2019 Nov;144(5). doi: 10.1542/peds.2019-1368. Epub 2019 Oct 16.
8
Physical changes, laboratory parameters, and bone mineral density during testosterone treatment in adolescents with gender dysphoria.在性别认同障碍的青少年中进行睾酮治疗期间的身体变化、实验室参数和骨密度。
J Sex Med. 2019 Sep;16(9):1459-1468. doi: 10.1016/j.jsxm.2019.06.014. Epub 2019 Aug 9.
9
Gender-affirming hormones and surgery in transgender children and adolescents.跨性别儿童和青少年的性别肯定激素治疗和手术。
Lancet Diabetes Endocrinol. 2019 Jun;7(6):484-498. doi: 10.1016/S2213-8587(18)30305-X. Epub 2018 Dec 6.
10
Ensuring Comprehensive Care and Support for Transgender and Gender-Diverse Children and Adolescents.保障跨性别和性别多样化儿童及青少年的全面关怀和支持。
Pediatrics. 2018 Oct;142(4). doi: 10.1542/peds.2018-2162. Epub 2018 Sep 17.

一项关于变性男孩使用促性腺激素释放激素类似物和睾酮的回顾性研究：对象、药物、时间及使用时长？

A Retrospective Study of the Use of Gonadotropin-Releasing Hormone Analogs and Testosterone in Transgender Boys: Who, What, When, and for How Long?

作者信息

Kain Emily J, Fuqua John S, Eugster Erica A

机构信息

Department of Pediatrics, Riley Hospital for Children at IU Health, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Division of Endocrinology, Department of Pediatrics, Riley Hospital for Children at IU Health, Indiana University School of Medicine, Indianapolis, Indiana, USA.

出版信息

Transgend Health. 2024 Aug 16;9(4):357-360. doi: 10.1089/trgh.2022.0156. eCollection 2024 Aug.

DOI:10.1089/trgh.2022.0156
PMID:39385958
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11456765/
Abstract

A retrospective review of gender-affirming hormone therapy was conducted in 101 transgender boys followed in the pediatric endocrine clinic. Eighty-seven percent were postmenarchal at the initial visit. Of the 44% prescribed gonadotropin-releasing hormone analogs (GnRHas), insurance coverage was denied in 34% and an average of 4.5 months elapsed before treatment could be started in the remainder. Patients prescribed GnRHas were younger than those who were not, 13.7±2.1 versus 15.5±2.0 years, <0.001. Continued menstrual bleeding was reported by patients receiving testosterone alone at doses ranging from 50 to 200 mg every 2 weeks.

摘要

对在儿科内分泌诊所随访的101名变性男孩进行了一项关于性别确认激素治疗的回顾性研究。87%的患者在初次就诊时已过月经初潮。在44%开具促性腺激素释放激素类似物（GnRHas）的患者中，34%的保险理赔被拒绝，其余患者平均经过4.5个月才开始治疗。开具GnRHas的患者比未开具的患者年龄更小，分别为13.7±2.1岁和15.5±2.0岁，P<0.001。接受每2周50至200毫克睾酮单药治疗的患者报告有持续月经出血。